To link to the regulatory effects of PROX1 on SIRT3, a protein known to regulate glucose metabolism, we showed that EZH2 promotes the remodeling of glucose metabolism in colon cancer cells, perhaps through its effects on SIRT3. These data imply that drugs targeting EZH2 may have downstream effects on cancer cell metabolism. The gene discussed is SIRT3; the disease is malignant colon neoplasm.